Summary (tl;dr)

A new study led by Dr. Shady Abohashem reveals a substantial gap between current cholesterol levels in the U.S. population and the stricter goals set by the recently released 2026 American Heart Association/American College of Cardiology (AHA/ACC) guidelines, indicating a widespread underuse of cholesterol-lowering medications.

Essential Background

The American Heart Association (AHA) and American College of Cardiology (ACC) regularly update their guidelines for managing cholesterol to mitigate the risk of cardiovascular disease. These updates, particularly those that lower recommended cholesterol levels, have historically sparked public and medical debate, often due to concerns about potentially broadening the population eligible for statin therapy and the influence of pharmaceutical companies. The latest 2026 ACC/AHA dyslipidemia guideline introduces a new cardiovascular risk calculator and sets lower target LDL (low-density lipoprotein) cholesterol levels, with an increased focus on earlier prevention strategies.

The Full Story

A recent study, spearheaded by Dr. Shady Abohashem of Mass General Brigham and Harvard Medical School, assessed how well the U.S. adult population aligns with the new 2026 ACC/AHA cholesterol guidelines. Published in JAMA, the findings indicate that nearly one-third of U.S. adults without a history of heart disease and almost four out of five individuals who have previously experienced a cardiovascular event currently have LDL cholesterol levels above these updated recommendations. Alarmingly, the study highlighted that approximately three-quarters of adults without heart disease who exceeded their LDL targets were not receiving any cholesterol-lowering medication. This analysis, based on national data from the 2021-2023 National Health and Nutrition Examination Survey (NHANES) covering about 178 million U.S. adults, underscores a significant deficiency in current lipid management and a substantial missed opportunity for preventing cardiovascular events.

Why It Matters

This study is crucial as it establishes a baseline for understanding the impact and adoption of the new 2026 cholesterol guidelines. The findings suggest that millions of Americans may require re-evaluation and potentially more intensive treatment to meet the lower LDL targets, which are designed to significantly reduce the risk of atherosclerotic cardiovascular disease, the leading global cause of death. The widespread under-treatment identified by Dr. Abohashem's team emphasizes the critical need for enhanced patient awareness, improved clinical implementation of guidelines, and efforts to overcome systemic barriers to accessing care in order to prevent future heart attacks and strokes.

Geographic Location

• Boston, Suffolk County, Massachusetts, United States (location of Mass General Brigham and Harvard Medical School, where lead author Dr. Shady Abohashem is affiliated and where the study was conducted)
• United States (population analyzed in the national study)